Coya Therapeutics, Inc. Coya Therapeutics, Inc.

Coya Therapeutics, Inc.

COYA

Rank in Stocks #20873
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on... Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Share Price
$3.27
Last synced: 2026-11-12
Market Cap
$76.71M
Change (1 day)
1.87%
Change (1 year)
-44.10%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Coya Therapeutics, Inc. (COYA)
EPS as of September 2026 TTM: $-1.39
According to Coya Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.39. At the end of 2025 the company had an EPS of $-1.27, a decrease compared to its 2024 EPS of $-0.98.
EPS history for Coya Therapeutics, Inc. from 2020 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-1.39 9.45%
2025 $-1.27 29.59%
2024 $-0.98 24.05%
2023 $-0.79 -35.82%
2022 $-1.23 66.34%
2021 $-0.74 76.19%
2020 $-0.42 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 -35.97%
US
$15.66 -1,226.62%
US
$-7.07 408.63%
US
$-5.29 280.58%
AU
$12.73 -1,015.99%
BE

Questions about Coya Therapeutics, Inc.'s earnings per share (EPS)

What is Coya Therapeutics, Inc.'s earnings per share (EPS)?

Coya Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.39, as of Sep 2026.

What was Coya Therapeutics, Inc.'s earnings per share (EPS) in 2025?

In 2025, Coya Therapeutics, Inc.'s earnings per share (EPS) was $-1.27, compared with $-0.98 in 2024.

How has Coya Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Coya Therapeutics, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.42) and lowest in 2025 ($-1.27).

How does Coya Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?

Coya Therapeutics, Inc.'s earnings per share (EPS) ($-1.39) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.